Introduction As one of the most active innovative drug development areas at present, Antibody-Drug Conjugates (ADCs) are rising at an astonishing pace. The global industry interest continues to heat up, with ADC innovative drugs being approved one after another. As of March 2025, a total of 17 ADC products have been approved for market release … Read more
According to a report from Health Times on February 14, the team led by Professor Peng Zhiyong at Zhongnan Hospital of Wuhan University is conducting clinical trials on high-dose Vitamin C treatment for COVID-19, suggesting that Vitamin C may be used for treating COVID-19. Professor Peng Zhiyong explained that the dosage of Vitamin C used … Read more
Recently, ADC (Antibody-Drug Conjugate) conferences have been held one after another, with major biotech companies competing to report their ADC pipelines. It is expected that 2024 will still be the main venue for ADCs. Developing an entry-level ADC seems not difficult, but evaluating the pharmacology and toxicology in the preclinical stage has become a top … Read more
Introduction Antibody-drug conjugates (ADC) are comprised of monoclonal antibodies that target specific antigens linked to small molecule cytotoxic drugs via a linker, combining the powerful killing effects of traditional small molecule chemotherapy with the tumor-targeting properties of antibody drugs. Since the first ADC (Gemtuzumab-ozogamicin (trade name: Mylotarg)) was approved for the treatment of CD33-positive acute … Read more
Antibody-drug conjugates (ADC) are formed by linking monoclonal antibodies that target specific antigens with small molecule cytotoxic drugs through linkers, combining the powerful killing effect of traditional small molecule chemotherapy with the tumor targeting ability of antibody drugs. Since the first ADC (Gemtuzumab-ozogamicin, trade name: Mylotarg) was approved for the treatment of CD33-positive acute myeloid … Read more
